How Is Amplia Therapeutics Advancing Pancreatic Cancer Treatment with $27.6M Raise?

• Half-year net loss widened to $4.18 million
• Raised $27.6 million through equity placement and share purchase plan
• Promising ACCENT trial interim results – 33% objective response rate, 7.6 months progression-free survival
• Initiated second AMPLICITY trial combining narmafotinib with FOLFIRINOX